KIM
REVB icon

Karpus Investment Management’s Revelation Biosciences REVB Stock Holding History

Karpus Investment Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$8.58M – 443
2021
Q4 		$8.58M Hold
4
– – 0.25% 98
2021
Q3 		$8.85M Hold
4
– – 0.26% 89
2021
Q2 		$7.75M Hold
4
– – 0.23% 103
2021
Q1 		$7.64M Buy
4
+1
+33% +$2.05M 0.23% 106
2020
Q4 		$5.24M Buy
+3
New +$6.05M 0.16% 113

Other funds holding REVB

Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Karpus Investment Management's REVB Position: Q1 2022 in Review

Karpus Investment Management sold out of Revelation Biosciences (REVB) in Q1 2022, closing a stake of 4 shares — an estimated $8.58M sold.

Karpus Investment Management first reported a position in REVB in Q4 2020 and held it in 5 quarters. The position peaked at $8.85M in Q3 2021. 2 funds tracked by Wall St. Rank hold REVB as of Q1 2022.

  • Karpus Investment Management reported no remaining Revelation Biosciences position as of Q1 2022 after selling out during the quarter.
  • Karpus Investment Management sold 4 Revelation Biosciences shares in Q1 2022, an estimated $8.58M.
  • Karpus Investment Management first reported a position in Revelation Biosciences in Q4 2020 and held it in 5 quarters.
  • Karpus Investment Management's Revelation Biosciences position peaked at $8.85M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2022.

Based on Karpus Investment Management's 13F filing for Q1 2022, filed 10 May 2022.